0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV242.94%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
AC Immune Stock Discussion
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an...
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
It's uptrending! Load up now before it's too late! Go Go Go!!!
NEWS
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Positive
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expe...
No comment yet